Multiple Sclerosis (MS) is an inflammatory, demyelinating disorder of the central nervous system (CNS). The etiology of MS remains unclear, but the disease develops in genetically susceptible individuals exposed to environmental triggers. The long favored hypothesis in MS implicates autoreactive T cells generated in the periphery that access the CNS, where they induce injury of previously normal neural tissues. However, in contrast to the animal model experimental autoimmune encephalomyelitis (EAE), neither the target(s) of the immune response nor the cells responsible for CNS damage have been identified in MS. Furthermore, the failure of some MS treatments targeting processes that underlie the development of CNS tissue destruction in EAE (e.g. IFN-g, TNF-a inhibitors) indicates that different mechanisms may cause the development of disability in MS versus EAE. Therefore, there is a need to identify pathophysiological mechanisms that are specific for MS, but may not be predicted from EAE. Therapeutic trials, especially those that investigate novel therapeutic agents, represent a unique opportunity to investigate how specific perturbations of the biological system affect MS disease process. The goal of this project is to carefully study the biological perturbations induced by the application of novel therapeutic agents in Phase I/II clinical trials in MS in order to define mechanisms of CNS tissue injury, but also those that underlie beneficial immunoregulation and immune-mediated neuroprotection. By correlating changes measured in the biological system (e.g. different functions of the T cells or other immune cell subsets) with structural changes of CNS destruction or repair (measured by neuroimaging modalities), and with clinical outcomes, we can understand which biological processes are beneficial and which are harmful in the MS pathogenesis. Additionally, understanding which effects of applied therapies underlie their therapeutic benefit will allow us to define biomarkers that are indicative, and ideally also predictive of the full therapeutic response. We are currently studying immunomodulatory properties of three therapeutic agents: daclizumab, idebenone and rituximab in 3 investigator-initiated Phase I/II clinical trials performed under Investigational New Drug (IND) application (PI, Bibiana Bielekova). Our results are briefly summarized below: Daclizumab is a humanized monoclonal Ab against CD25, which is the alpha chain of the IL-2 receptor (IL-2R). CD25 is highly upregulated on activated T cells and contribution of CD25 to high-affinity IL-2 signaling was believed to be paramount for expansion of effector T cells. Thus, it was expected that daclizumab therapy will result in inhibition of T cell functions. While we have demonstrated that daclizumab is highly effective in suppressing MS-related inflammatory activity, this effect was not paralleled by inhibition of T cells. Instead, daclizumab selectively expands CD56bright natural killer (NK) cells and that this human-specific NK cell population has immunoregulatory function through its ability to kill activated autologous T cells. This year we published that NK cells utilize new mechanism (Granzyme-K;GzK) for killing T cells and that GzK expression is selectively upregulated by daclizumab treatment. The expansion of CD56bright NK cells correlated with treatment outcome, suggestive that it can be utilized as biomarker of therapeutic response. This observation has now been fully reproduced in double-blind, placebo-controlled multicenter Phase II/IIb trials of daclizumab in MS. We continue to study the mechanism of action (MOA) of daclizumab in MS in therapeutic trial of DAC-HYP (second generation of daclizumab) in patients with MS (protocol 10-N-0125), with the goal to determine all effects of daclizumab on human immune system. Through this work we recently described another fascinating MOA, which also reveals novel aspects of IL-2 biology: daclizumab blocks activation of T cells by inhibiting CD25 expression on activated (i.e. mature) myeloid dendritic cells (mDCs). mDCs express CD25 and can produce IL-2, but cannot consume it because they lack another important singling chain, CD122. Instead, mDCs use their CD25 to transpresent IL-2, which they secrete into immune synapse, to a T cell that is being activated in antigen-specific manner. This IL-2 signal, given in conjunction with T cell receptor and costimulatory stimuli then allows T cell to enter proliferation cycle and clonally expand. In addition of mechanistic studies of daclizumab, in other two clinical trials we are trying to understand which mechanisms drive progression of disability and CNS tissue destruction in progressive MS. Primary-progressive MS (PP-MS) is resistant to therapy by immunomodulatory agents. Mitochondrial dysfunction coupled with oxidative stress has been proposed as one of the top alternative hypotheses underlying pathophysiology of PP-MS. Idebenone is a lipid soluble synthetic analogue of coenzyme-Q (CoQ). As such, it both improves mitochondrial metabolism and has an antioxidant effect. Therefore, in protocol 09-N-0197, we test the hypothesis whether mitochondrial dysfunction and oxidative stress contribute to development of neurological disability in PP-MS. Efficacy of idebenone in suppressing oxidative stress intrathecally and its unexplored immunomodulatory effects are being measured by ex-vivo analysis of PBMC functions and CSF biomarkers in enrolled patients. Rituximab is a B cell depleting chimeric monoclonal Ab and has inhibitory effect on MS disease activity in patients with evidence of blood-brain barrier (BBB) breakdown. The current leading hypothesis is that B cells collaborate with antigen-specific T cells and support T cell activation through antigen-presentation functions and mutual co-stimulation. Furthermore, there is evidence that in secondary-progressive MS (SP-MS) patients B cells and T cells form tertiary lymphoid follicles deep within the brain sulci. These ectopic lymphoid follicles recapitulate activation of antigen-specific T and B cells within the intrathecal compartment. Unfortunately, because majority of progressive MS patients do not have overt BBB disruption, only about 0.1% of systemically administered rituximab gains access to CNS compartment, which is not sufficient to deplete CNS B cells. Therefore, we are testing the hypothesis that intrathecal administration of rituximab in patients with SP-MS will effectively deplete B cells in the CNS compartment and this will translate into therapeutic effect of rituximab on biomarkers of CNS tissue injury in the placebo-controlled, Phase II trial of rituximab in low-inflammatory SP-MS (protocol 10-N-0212). While there are many agents that have biologically plausible MOA for testing their efficacy in progressive MS, the drug development is currently hampered by the fact that we have no sensitive interim outcome measure. Therefore, current Phase II studies in progressive MS require enrollment of hundreds of MS patients and are prohibitively expensive. Both of our double-blind placebo-controlled investigator-initiated Phase II clinical trials (i.e. idebenone and IT rituximab) share identical adaptive trial design focusing on the evaluation of different (mostly novel) quantitative clinical, functional and imaging outcome measures. The hope is that collected data from these 2 studies will help to define new, more effective clinical trial design for future Phase II therapeutic trials in progressive MS.
| Romme Christensen, Jeppe; Komori, Mika; von Essen, Marina Rode et al. (2018) CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage. Mult Scler :1352458518774880 |
| Bielekova, Bibiana (2018) Daclizumab Therapy for Multiple Sclerosis. Cold Spring Harb Perspect Med : |
| Waters, Ryan S; Perry, Justin S A; Han, SunPil et al. (2018) The effects of interleukin-2 on immune response regulation. Math Med Biol 35:79-119 |
| Weideman, Ann Marie; Barbour, Christopher; Tapia-Maltos, Marco Aurelio et al. (2017) New Multiple Sclerosis Disease Severity Scale Predicts Future Accumulation of Disability. Front Neurol 8:598 |
| Komori, Mika; Kosa, Peter; Stein, Jason et al. (2017) Pharmacodynamic effects of daclizumab in the intrathecal compartment. Ann Clin Transl Neurol 4:478-490 |
| Weideman, Ann Marie; Tapia-Maltos, Marco Aurelio; Johnson, Kory et al. (2017) Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments. Front Neurol 8:577 |
| Tanigawa, Makoto; Stein, Jason; Park, John et al. (2017) Finger and foot tapping as alternative outcomes of upper and lower extremity function in multiple sclerosis. Mult Scler J Exp Transl Clin 3:2055217316688930 |
| Komori, Mika; Lin, Yen Chih; Cortese, Irene et al. (2016) Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Ann Clin Transl Neurol 3:166-79 |
| Bielekova, Bibiana; Tintore, Mar (2016) Sustained reduction of MS disability: New player in comparing disease-modifying treatments. Neurology 87:1966-1967 |
| Cortese, Irene; Ohayon, Joan; Fenton, Kaylan et al. (2016) Cutaneous adverse events in multiple sclerosis patients treated with daclizumab. Neurology 86:847-55 |
Showing the most recent 10 out of 34 publications
